

Investors Update

Manufacturing

The company has successfully completed the manufacturing process at Mego Afek and is now preparing to the next manufacturing run that will support the new FIH trial in Israel and the soft launch in the US.



FDA tests

The LapBox units have started the testing cycle for the FDA approval in laboratories around the world and so far preliminary results are all good.

First animal Trial in the US:

The company performed a successful first animal trial in the US with Dr. Michael Sprague from the Cleveland clinic that was trained by the company representative Dr. Amy Garcia. The trial included the LapBox training followed by an animal trial where both power and manual morcellation were performed.



Team:

- Ark is proud to announce that Dr. Edward Evantash has joined the company as a CMO (chief medical officer) (<https://www.linkedin.com/in/edward-evtash-278b6910/>). Edward served for more than 10 years as Hologic (Nasdaq ~\$20B) CMO (<https://www.hologic.com/>). Edward is a leading figure in the medical device community and brings with him vast knowledge of product development and personal connections to leading medical centers.

Future:

- Ark continue to work on its market penetration plan for the soft launch and sales of LapBox units in the US and is collaborating with sales and marketing experts from Israel and the US.
- The company will soon launch its new website and marketing materials
- Ark is attending the biggest GYN convention, AAGL, (<https://congress.aagl.org/aagl-2021-landing-page/>) where it will present the new LapBox version to strategic partners and global medical device companies that are its potential buyers.